Arcutis Biotherapeutics (NASDAQ:ARQT) has observed the following analyst ratings within the last quarter:
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
These 6 analysts have an average price target of $34.83 versus the current price of Arcutis Biotherapeutics at $3.3701, implying upside.
Below is a summary of how these 6 analysts rated Arcutis Biotherapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This current average represents a 28.19% decrease from the previous average price target of $48.50.
Stay up to date on Arcutis Biotherapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
